Maker of Botox acquires Tobira

Botox-maker Allergan is bulking up its drug pipeline by acquiring Tobira Therapeutics Inc. and two potential liver disease treatments in a deal that could be worth almost US$1.7 billion. Tobira is testing two treatments for non-alcoholic steatohepatitis, a disease that can lead to cirrhosis, cancer and eventual liver failure.